© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
May 08, 2021
Research at ARVO 2021 highlighted a gamut of interplaying diabetes and vision loss risk factors, and even treatments for both. But experts depict a referral and care process that lacks whole diabetes care.
May 07, 2021
A podcast interview with study author Paul Yang, MD, PhD, on the current research and future implementation of the agent.
Data from the KITE study shows that ≥50% of brolucizumab patients maintained a 12-week interval schedule through 52 weeks.
Patients who utilized virtual and in-person visits had comparable numbers of follow-ups, referrals, and outpatient surgeries.
May 06, 2021
The implant was linked to visual acuity improvements at final follow-up visit.
Animal models suggest the investigative treatment is safe and tolerable in treating retinal vascular diseases.
There were no significant differences between dexamethasone and fluocinolone acetonide intravitreal implants in controlling inflammation; however, the latter is considered more difficult to use.
May 05, 2021
A discussion with an investigator on how the SGLT-2 inhibitor may help affected patients.
Up to 77% of patients maintained or improved best-corrected visual acuity at 12 month post-injection.
Hispanic and Black patients with chronic eye diseases had higher odds of missing out on appointments.